Pharma company Dr. Reddy’s Laboratories Ltd. today announced a 66.58 per cent rise in its net profit to Rs 570.89 crore for the quarter ended March 31, 2013 mainly on account of robust sales across all segments.
Revenue for the three-month period gained 26 percent to Rs 3,340 crore, the company said in a statement. The company’s major segments include global generics, pharmaceutical services and active ingredients.
The company’s other income in the quarter jumped to Rs 163 crore in Jan-March, compared with Rs 20 crore in the year ago quarter. Profit was also boosted by near 400 percent jump in net finance income at Rs 40 crore. Its gross profit was up 21 percent to Rs 1,684 crore.
The company said its Board of Directors have recommended a final dividend of Rs 15 per share of Rs 5 face value, for the financial year 2012-13. In the fourth quarter, Dr Reddy’s launched 18 new generic products and filed 14 new product registrations. (INN)